#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glomerulonephritis acute Anti-myelin-associated glycoprotein antibodies positive Primary myelofibrosis Acute promyelocytic leukaemia Hepatocellular carcinoma Chondrodystrophy Hepato-lenticular degeneration Hypophosphatasia Hereditary motor and sensory neuropathy Small cell lung cancer extensive stage Thrombocytosis Fragile X syndrome Neonatal alloimmune thrombocytopenia Usher's syndrome Chronic myelomonocytic leukaemia More trials…

    Learn about Rare Diseases

    Aicardi-Goutieres syndrome – Life with Disease Mantle cell lymphoma refractory Carcinoid syndrome – Basic Information Mucopolysaccharidosis III – Trials in Disease Rett syndrome – Basic Information Gaucher’s disease type I – Basic Information Glomerulonephritis membranoproliferative Loeys-Dietz syndrome – Trials in Disease Nephrotic syndrome – Diagnostics Hepatoblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Doxazosin Mesilate Sodium Oxybate IBANDRONIC ACID Bt-001 X-396 Theophylline Selinexor Acetazolamide Sodium Egl-001 Dermatophagoides Pteronyssinus Interferon Alfa R2R01 Dextrose Bp Tilmanocept Leriglitazone Anhydrous Benzoyl Peroxide Anselamimab Larotrectinib Sulfate Brigatinib VG801-2 More therapies…

    Learn about Your Condition

    Pulmonary congestion Rheumatic disorder Laparoscopic surgery Retinal vein occlusion Blood iron increased Transient ischaemic attack Thromboangiitis obliterans Compulsive sexual behaviour Triple negative breast cancer Endocarditis Osteosarcoma recurrent Angiosarcoma metastatic Cartilage injury Adrenocortical carcinoma Streptococcal infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Ovarian cancer recurrent

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Peritoneal cancer index
    • Ovarian cancer recurrent
    • Endometrial cancer
    Investigated Drugs:
    • Sarilumab
    • Ubamatamab
    • Cemiplimab
    Belgium France Italy The Netherlands Spain

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer recurrent
    • Ovarian cancer recurrent
    Investigated Drugs:
    • H2-Receptor Antagonists
    • Sacituzumab Tirumotecan
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +8

  • Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Cisplatin
    Italy

  • Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Olaparib
    Italy

  • Study on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    • Breast cancer metastatic
    • Ovarian cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Eribulin Mesylate
    • Doxorubicin Hydrochloride, Liposomal
    Portugal

  • Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or Ubamatamab for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Peritoneal cancer index
    • Ovarian cancer recurrent
    • Fallopian tube cancer
    Investigated Drugs:
    • Regn5668
    • Sarilumab
    • Fianlimab
    Belgium France Spain
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!